MARKET WIRECNBC • 3h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why RCKT Stock slipped -1.55% Today — RQD Quant Desk Flash
$2.54 -1.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.53
Rocket Pharmaceuticals Inc. (RCKT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $278.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.53 (-0.47%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RCKT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY RCKT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (32% of score)
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 45.2 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (23% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.56-14.8% Next Q
39
Q2 (-2Q)Grade E$2.18+5% Next Q
36
Q3 (-1Q)Grade E$2.29+10.9% Next Q
34
CurrentGrade E$2.54-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RCKT Turnaround Squeeze
While RCKT currently carries a cautious 31/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.96) and Max Pain ($2.67) forces dealer call-delta covering toward $5.72.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RCKT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RCKT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RCKT Stock slipped -1.55% Today — RQD Quant Desk Flash
Rocket Pharmaceuticals Inc. (RCKT) slipped -1.55% to $2.54, trading at 11% of its 52-week range ($2.17 – $5.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($2.17 – $5.45) with RSI-14 at 45.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.54 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RCKT Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RCKT)
- ✓Walkthrough of RCKT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RCKT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.01%▼ DESCENDING CHANNEL
2026-10-30O $2.50H $2.57L $2.37C $2.54VOL 1.53M
RES: $3.57SUP: $2.02SMA50: $2.96SMA200: $3.45
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RCKT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RCKT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RCKT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RCKT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RCKT)
Health Care Rank #920 of 1016
⚔️ GLSI vs RCKT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RCKT vs. GLSI, LRMR, LYEL, BIOA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Rocket Pharmaceuticals Inc. (RCKT) ranks #920 by composite RQD confidence (31/100, grade E) and #529 by equity capitalization ($278.8M). Within this direct 5-issuer industry benchmark cohort, RCKT leads on earnings valuation at N/A trailing P/E, while RCKT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LRMR currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with RCKT at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RCKT
ACTIVE
Rocket Pharmaceuticals Inc. | E | 31/100 | — | — | -35.0% | -1.55% | $278.8M | Benchmark Subject |
| GLSI Greenwich LifeSciences Inc. | D- | 41/100 | — | — | -35.0% | +3.77% | $278.9M | /glsi-vs-rckt → |
| LRMR Larimar Therapeutics Inc. | D | 50/100 | — | — | -35.0% | +5.12% | $277.4M | /lrmr-vs-rckt → |
| LYEL Lyell Immunopharma Inc. | D- | 38/100 | — | — | -35.0% | +3.43% | $277.0M | /lyel-vs-rckt → |
| BIOA BioAge Labs Inc. | D | 44/100 | — | — | -35.0% | 0.00% | $272.6M | /bioa-vs-rckt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001281895In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rocket Pharmaceuticals Inc. (RCKT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$223.1M, operating cash flow of -$190.0M, and free cash flow of -$190.5M (+11.7% YoY). On the balance sheet, RCKT closed FY2025 with $330.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$223.1M | -$190.0M | -$190.5M | $330.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$258.7M | -$209.7M | -$215.6M | $527.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$245.6M | -$194.9M | -$194.9M | — | — |
3. RCKT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RCKT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.54 (-1.55% 1D, market cap $278.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RCKT ranks #920 in composite RQD confidence.
How does RCKT compare to GLSI and LRMR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCKT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GLSI (Greenwich LifeSciences Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $278.9M) and LRMR (Larimar Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $277.4M). Among the 5-stock peer group, RCKT leads on earnings multiple (N/A) while RCKT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RCKT?
Per RCKT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001281895), Rocket Pharmaceuticals Inc. generated $0 in revenue, -$223.1M in net income, and -$190.5M in free cash flow against $330.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RCKT trading relative to its 50-day, 200-day, and 52-week technical levels?
RCKT last traded at $2.54 (-1.55% on volume of 1,830,123 shares), positioning the stock -14.19% below its 50-day simple moving average ($2.96) and -26.38% below its 200-day simple moving average ($3.45). Across its 52-week range of $2.17 to $5.45, RCKT sits at the 11.3% percentile with a 14-day RSI of 45.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.22 to $2.86).
RCKT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RCKT stock moving today?
Why RCKT Stock slipped -1.55% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.